Sotorasib shows clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer
In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic cancer, according to researchers at Â鶹ӳ» MD Anderson Cancer Center.
The results of the trial, published today in the The New England Journal of Medicine, indicate an objective response rate...
